Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors

Immune checkpoint inhibitors (ICI) used for cancer immunotherapy were shown to boost the existing anti-tumor immune response by preventing the inhibition of T cells by tumor cells. Antibodies targeting two negative immune checkpoint pathways, namely cytotoxic T-lymphocyte-associated protein 4 (CTLA-...

Full description

Saved in:
Bibliographic Details
Main Authors: Bitsch, Rebekka (Author) , Fleming, Viktor (Author) , Hu, Xiaoying (Author) , Groth, Christopher (Author) , Altevogt, Peter (Author) , Utikal, Jochen (Author) , Umansky, Viktor (Author)
Format: Article (Journal)
Language:English
Published: 11 June 2018
In: Frontiers in immunology
Year: 2018, Volume: 9
ISSN:1664-3224
DOI:10.3389/fimmu.2018.01310
Online Access:Verlag, Volltext: http://dx.doi.org/10.3389/fimmu.2018.01310
Get full text
Author Notes:Rebekka Weber, Viktor Fleming, Xiaoying Hu, Vasyl Nagibin, Christopher Groth, Peter Altevogt, Jochen Utikal, Viktor Umansky

MARC

LEADER 00000caa a2200000 c 4500
001 1668133741
003 DE-627
005 20220816180727.0
007 cr uuu---uuuuu
008 190701s2018 xx |||||o 00| ||eng c
024 7 |a 10.3389/fimmu.2018.01310  |2 doi 
035 |a (DE-627)1668133741 
035 |a (DE-599)KXP1668133741 
035 |a (OCoLC)1341231514 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Bitsch, Rebekka  |d 1991-  |e VerfasserIn  |0 (DE-588)1163544582  |0 (DE-627)1027872069  |0 (DE-576)508043565  |4 aut 
245 1 0 |a Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors  |c Rebekka Weber, Viktor Fleming, Xiaoying Hu, Vasyl Nagibin, Christopher Groth, Peter Altevogt, Jochen Utikal, Viktor Umansky 
264 1 |c 11 June 2018 
300 |a 9 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 01.07.2019 
520 |a Immune checkpoint inhibitors (ICI) used for cancer immunotherapy were shown to boost the existing anti-tumor immune response by preventing the inhibition of T cells by tumor cells. Antibodies targeting two negative immune checkpoint pathways, namely cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed cell death-ligand 1 (PD-L1), have been approved first for patients with melanoma, squamous non-small cell lung cancer (NSCLC), and renal cell carcinoma. Clinical trials are ongoing to verify the efficiency of these antibodies for other cancer types and to evaluate strategies to block other checkpoint molecules. However, a number of patients do not respond to this treatment possibly due to profound immunosuppression, which is mediated partly by myeloid-derived suppressor cells (MDSC). This heterogeneous population of immature myeloid cells can strongly inhibit anti-tumor activities of T and NK cells and stimulate regulatory T cells (Treg), leading to tumor progression. Moreover, MDSC can contribute to patient resistance to immune checkpoint inhibition. Accumulating evidence demonstrates that the frequency and immunosuppressive function of MDSC in cancer patients can be used as a predictive marker for therapy response. This review focuses on the role of MDSC in immune checkpoint inhibition and provides an analysis of combination strategies for MDSC targeting together with ICI to improve their therapeutic efficiency in cancer patients. 
650 4 |a cancer immunotherapy 
650 4 |a combination therapy 
650 4 |a immune checkpoint inhibition 
650 4 |a immunosuppression 
650 4 |a myeloid-derived suppressor cells 
700 1 |a Fleming, Viktor  |e VerfasserIn  |0 (DE-588)1164193791  |0 (DE-627)1028658206  |0 (DE-576)508433266  |4 aut 
700 1 |a Hu, Xiaoying  |d 1990-  |e VerfasserIn  |0 (DE-588)1188900889  |0 (DE-627)1667767593  |4 aut 
700 1 |a Groth, Christopher  |d 1989-2025  |e VerfasserIn  |0 (DE-588)1156675456  |0 (DE-627)1019506482  |0 (DE-576)502360151  |4 aut 
700 1 |a Altevogt, Peter  |d 1947-  |e VerfasserIn  |0 (DE-588)1113206306  |0 (DE-627)867118784  |0 (DE-576)164729240  |4 aut 
700 1 |a Utikal, Jochen  |d 1974-  |e VerfasserIn  |0 (DE-588)1026463750  |0 (DE-627)726765015  |0 (DE-576)371816580  |4 aut 
700 1 |a Umansky, Viktor  |d 1955-  |e VerfasserIn  |0 (DE-588)102885756X  |0 (DE-627)731733207  |0 (DE-576)376300078  |4 aut 
773 0 8 |i Enthalten in  |t Frontiers in immunology  |d Lausanne : Frontiers Media, 2010  |g 9(2018) Artikel-Nummer 1310, 9 Seiten  |h Online-Ressource  |w (DE-627)657998354  |w (DE-600)2606827-8  |w (DE-576)343624834  |x 1664-3224  |7 nnas  |a Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors 
773 1 8 |g volume:9  |g year:2018  |g extent:9  |a Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors 
856 4 0 |u http://dx.doi.org/10.3389/fimmu.2018.01310  |x Verlag  |x Resolving-System  |3 Volltext 
951 |a AR 
992 |a 20190701 
993 |a Article 
994 |a 2018 
998 |g 102885756X  |a Umansky, Viktor  |m 102885756X:Umansky, Viktor  |d 60000  |d 61900  |d 140000  |e 60000PU102885756X  |e 61900PU102885756X  |e 140000PU102885756X  |k 0/60000/  |k 1/60000/61900/  |k 0/140000/  |p 8  |y j 
998 |g 1026463750  |a Utikal, Jochen  |m 1026463750:Utikal, Jochen  |d 60000  |e 60000PU1026463750  |k 0/60000/  |p 7 
998 |g 1113206306  |a Altevogt, Peter  |m 1113206306:Altevogt, Peter  |d 60000  |d 61900  |d 50000  |e 60000PA1113206306  |e 61900PA1113206306  |e 50000PA1113206306  |k 0/60000/  |k 1/60000/61900/  |k 0/50000/  |p 6 
998 |g 1156675456  |a Groth, Christopher  |m 1156675456:Groth, Christopher  |d 60000  |d 61900  |e 60000PG1156675456  |e 61900PG1156675456  |k 0/60000/  |k 1/60000/61900/  |p 5 
998 |g 1163544582  |a Bitsch, Rebekka  |m 1163544582:Bitsch, Rebekka  |d 60000  |d 61900  |e 60000PB1163544582  |e 61900PB1163544582  |k 0/60000/  |k 1/60000/61900/  |p 1  |x j 
999 |a KXP-PPN1668133741  |e 3490298055 
BIB |a Y 
SER |a journal 
JSO |a {"note":["Gesehen am 01.07.2019"],"title":[{"title_sort":"Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors","title":"Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors"}],"id":{"doi":["10.3389/fimmu.2018.01310"],"eki":["1668133741"]},"recId":"1668133741","relHost":[{"language":["eng"],"origin":[{"dateIssuedDisp":"2010-","publisherPlace":"Lausanne","dateIssuedKey":"2010","publisher":"Frontiers Media"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"part":{"year":"2018","extent":"9","volume":"9","text":"9(2018) Artikel-Nummer 1310, 9 Seiten"},"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["1664-3224"],"eki":["657998354"],"zdb":["2606827-8"]},"title":[{"title":"Frontiers in immunology","title_sort":"Frontiers in immunology"}],"disp":"Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitorsFrontiers in immunology","note":["Gesehen am 07.11.13"],"recId":"657998354","pubHistory":["1.2010 -"]}],"person":[{"given":"Rebekka","role":"aut","display":"Bitsch, Rebekka","roleDisplay":"VerfasserIn","family":"Bitsch"},{"role":"aut","display":"Fleming, Viktor","given":"Viktor","roleDisplay":"VerfasserIn","family":"Fleming"},{"display":"Hu, Xiaoying","role":"aut","given":"Xiaoying","family":"Hu","roleDisplay":"VerfasserIn"},{"role":"aut","display":"Groth, Christopher","given":"Christopher","roleDisplay":"VerfasserIn","family":"Groth"},{"given":"Peter","role":"aut","display":"Altevogt, Peter","family":"Altevogt","roleDisplay":"VerfasserIn"},{"display":"Utikal, Jochen","role":"aut","given":"Jochen","family":"Utikal","roleDisplay":"VerfasserIn"},{"family":"Umansky","roleDisplay":"VerfasserIn","given":"Viktor","role":"aut","display":"Umansky, Viktor"}],"name":{"displayForm":["Rebekka Weber, Viktor Fleming, Xiaoying Hu, Vasyl Nagibin, Christopher Groth, Peter Altevogt, Jochen Utikal, Viktor Umansky"]},"physDesc":[{"extent":"9 S."}],"language":["eng"],"origin":[{"dateIssuedDisp":"11 June 2018","dateIssuedKey":"2018"}],"type":{"media":"Online-Ressource","bibl":"article-journal"}} 
SRT |a BITSCHREBEMYELOIDDER1120